What You Should Know:
– Twin Health, a company known for its Digital Twin™ AI platform that helps individuals achieve remission of type 2 diabetes, has announced promising results in a new study focused on hypertension.
– Published in the Journal of the American College of Cardiology, the study demonstrates that the platform can effectively help users control blood pressure and reduce their reliance on medication.
Addressing the Link Between Diabetes and Hypertension
High blood pressure is a common comorbidity for people with type 2 diabetes, with approximately 74% experiencing hypertension or requiring medication to manage it. This combination significantly increases the risk of serious cardiovascular complications, including heart attack, stroke, and blindness.
While lifestyle changes can be effective in managing both conditions, many patients continue to rely on multiple medications. Twin Health offers a novel approach with its Digital Twin™ technology, which focuses on addressing the underlying metabolic issues that contribute to both type 2 diabetes and hypertension.
Study Findings
This secondary analysis of a one-year randomized controlled trial involved 59 patients with type 2 diabetes who were also taking medication for high blood pressure. The results showed that those using the Digital Twin™ AI platform achieved significantly higher rates of normalized blood pressure compared to the control group (40.9% vs. 6.7%).
How Digital Twin™ Works
The Digital Twin™ platform creates a personalized AI model of each member’s metabolism. By continuously collecting and analyzing data from wearable sensors and other sources, the platform provides tailored recommendations to guide users toward healthier habits.
Through an easy-to-use app, members receive real-time insights and support in areas such as nutrition, sleep, activity, and stress management. They also work closely with a dedicated care team for ongoing guidance and encouragement. This personalized approach empowers individuals to make sustainable lifestyle changes that address the root causes of their metabolic conditions.
“The impact of these results is not confined to just a blood pressure and blood sugar lowering effect, but also – and most importantly – addresses critical drivers of chronic metabolic disease to shift the emphasis from costly polypharmacy to sustainable, affordable, and effective lifestyle change,” said Dr. Jeff Mechanick, lead author of the study and Medical Director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital in New York City.
